Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
18 April 2024
|
|
m 08:39 | Non-degenerate nucleotides per response element 2 changes history +990 [Marshallsumter (2×)] | |||
| m |
|
08:39 (cur | prev) +727 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:35 (cur | prev) +263 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 06:18 | Endocarditis overview diffhist +2,588 Kosar Doraghi talk contribs | ||||
17 April 2024
|
|
N 20:47 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 3 changes history +364 [Hafiza Amna Qadeer (3×)] | |||
|
|
20:47 (cur | prev) −13 Hafiza Amna Qadeer talk contribs (minor edit) Tag: Visual edit | ||||
|
|
20:46 (cur | prev) +377 Hafiza Amna Qadeer talk contribs (new page minor edit) Tag: Visual edit | ||||
| N |
|
19:33 (cur | prev) 0 Hafiza Amna Qadeer talk contribs (Created blank page) | |||
|
|
m 18:11 | Non-degenerate nucleotides per response element 2 changes history +601 [Marshallsumter (2×)] | |||
| m |
|
18:11 (cur | prev) +438 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
06:52 (cur | prev) +163 Marshallsumter talk contribs (→Tabulation of counts) | |||
| N 08:08 | Elranatamab-bcmm diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:08 | Palovarotene diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:08 | Pozelimab-bbfg diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:07 | Motixafortide diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:07 | Momelotinib diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:06 | Cipaglucosidase alfa-atga diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:05 | Etrasimod diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:05 | Zilucoplan diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Bimekizumab diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Vamorolone diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Mirikizumab-mrkz diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:03 | Toripalimab-tpzi diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
|
|
08:02 | User:Edzelco 5 changes history +99 [Edzelco (5×)] | |||
|
|
08:02 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:53 (cur | prev) +26 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:44 (cur | prev) 0 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:44 (cur | prev) +36 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:43 (cur | prev) +19 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 08:02 | Fruquintinib diffhist +25,648 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...") | ||||
|
|
N 07:53 | Taurolidine, heparin 2 changes history +9,993 [Edzelco (2×)] | |||
|
|
07:53 (cur | prev) 0 Edzelco talk contribs | ||||
| N |
|
07:52 (cur | prev) +9,993 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...") | |||
| N 07:43 | Repotrectinib diffhist +32,783 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...") | ||||
|
|
N 07:34 | Efbemalenograstim alfa-vuxw 3 changes history +20,126 [Edzelco (3×)] | |||
|
|
07:34 (cur | prev) 0 Edzelco talk contribs | ||||
|
|
07:33 (cur | prev) +51 Edzelco talk contribs | ||||
| N |
|
07:32 (cur | prev) +20,075 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....") | |||
| 04:20 | Endocarditis overview diffhist +9,001 Kosar Doraghi talk contribs | ||||
16 April 2024
|
|
m 17:29 | Non-degenerate nucleotides per response element 2 changes history +606 [Marshallsumter (2×)] | |||
| m |
|
17:29 (cur | prev) +201 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:14 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
15:06 | Trismus 3 changes history +1,038 [M. Arsalan Bashir (3×)] | |||
|
|
15:06 (cur | prev) 0 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
15:00 (cur | prev) +223 M. Arsalan Bashir talk contribs | ||||
|
|
13:30 (cur | prev) +815 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
05:50 | User:Edzelco 2 changes history +33 [Edzelco (2×)] | |||
|
|
05:50 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
05:28 (cur | prev) +15 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 05:50 | Capivasertib diffhist +34,175 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...") | ||||
| N 05:27 | Iptacopan diffhist +33,311 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...") | ||||
| 01:37 | Birch triterpenes diffhist +1,569 Rafael Garcia talk contribs | ||||
15 April 2024
|
|
m 20:06 | Non-degenerate nucleotides per response element 2 changes history +1,954 [Marshallsumter (2×)] | |||
| m |
|
20:06 (cur | prev) +875 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:42 (cur | prev) +1,079 Marshallsumter talk contribs | |||
| 18:43 | Hand contracture diffhist −11 Dj talk contribs | ||||
| 07:25 | User:Edzelco diffhist +16 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 07:24 | Vutrisiran diffhist +17,228 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...") | ||||
14 April 2024
|
|
m 20:07 | Non-degenerate nucleotides per response element 3 changes history +2,087 [Marshallsumter (3×)] | |||
| m |
|
20:07 (cur | prev) +100 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
17:58 (cur | prev) +512 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:09 (cur | prev) +1,475 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:41 | Somatic symptom disorder diffhist +992 Badgettrg talk contribs (→Overview) | ||||
| 14:19 | Systematic review diffhist +554 Badgettrg talk contribs (→Meta-narrative reviews) | ||||
13 April 2024
|
|
m 17:15 | Non-degenerate nucleotides per response element 2 changes history +435 [Marshallsumter (2×)] | |||
| m |
|
17:15 (cur | prev) +324 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:00 (cur | prev) +111 Marshallsumter talk contribs (→Tabulation of counts) | |||
12 April 2024
|
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +1,137 [Marshallsumter (2×)] | |||
| m |
|
20:10 (cur | prev) +538 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:45 (cur | prev) +599 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 05:15 | User talk:Matt Pijoan diffhist +1,485 Marshallsumter talk contribs (→MALT1: new section) | ||||
11 April 2024
| 20:06 | User creation log User account Bilal Farhat Ali talk contribs was created by Alberto Castro Molina talk contribs | ||||